Similar articles for PMID: 30964126

Year	Number of Results
2017	1
2018	5
2019	16
2020	20
2021	32
2022	3
2023	1
2024	0

1

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.

Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. Fucà G, et al. ESMO Open. 2019 Feb 27;4(1):e000457. doi: 10.1136/esmoopen-2018-000457. eCollection 2019. ESMO Open. 2019. PMID: 30964126 Free PMC article.

2

Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.

Chu X, Zhao J, Zhou J, Zhou F, Jiang T, Jiang S, Sun X, You X, Wu F, Ren S, Zhou C, Su C. Chu X, et al. Lung Cancer. 2020 Dec;150:76-82. doi: 10.1016/j.lungcan.2020.08.015. Epub 2020 Aug 23. Lung Cancer. 2020. PMID: 33080551

3

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.

Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM. Kazandjian D, et al. JAMA Oncol. 2019 Oct 1;5(10):1481-1485. doi: 10.1001/jamaoncol.2019.1747. JAMA Oncol. 2019. PMID: 31343662 Free PMC article.

4

Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases.

Lauko A, Thapa B, Sharma M, Muhsen B, Barnett A, Rauf Y, Borghei-Razavi H, Tatineni V, Patil P, Mohammadi A, Chao S, Murphy ES, Angelov L, Suh J, Barnett GH, Nowacki AS, Pennell N, Ahluwalia MS. Lauko A, et al. Sci Rep. 2021 Apr 5;11(1):7490. doi: 10.1038/s41598-021-85328-w. Sci Rep. 2021. PMID: 33820922 Free PMC article.

5

Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.

Sacdalan DB, Lucero JA, Sacdalan DL. Sacdalan DB, et al. Onco Targets Ther. 2018 Feb 23;11:955-965. doi: 10.2147/OTT.S153290. eCollection 2018. Onco Targets Ther. 2018. PMID: 29503570 Free PMC article. Review.

6

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).

Li Y, Zhang Z, Hu Y, Yan X, Song Q, Wang G, Chen R, Jiao S, Wang J. Li Y, et al. Front Oncol. 2020 Jun 23;10:654. doi: 10.3389/fonc.2020.00654. eCollection 2020. Front Oncol. 2020. PMID: 32656072 Free PMC article.

7

The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.

Jacobi O, Landman Y, Reinhorn D, Icht O, Sternschuss M, Rotem O, Finkel I, Allen AM, Dudnik E, Goldstein DA, Zer A. Jacobi O, et al. Oncology. 2021;99(9):555-561. doi: 10.1159/000516671. Epub 2021 Jul 9. Oncology. 2021. PMID: 34247166

8

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.

Ayers KL, Ma M, Debussche G, Corrigan D, McCafferty J, Lee K, Newman S, Zhou X, Hirsch FR, Mack PC, Liu JJ, Schadt EE, Chen R, Li SD. Ayers KL, et al. BMC Cancer. 2021 Apr 21;21(1):441. doi: 10.1186/s12885-021-08194-9. BMC Cancer. 2021. PMID: 33882890 Free PMC article.

9

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.

Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L. Pavan A, et al. Oncologist. 2019 Aug;24(8):1128-1136. doi: 10.1634/theoncologist.2018-0563. Epub 2019 Apr 23. Oncologist. 2019. PMID: 31015312 Free PMC article.

10

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.

Wang SJ, Khullar K, Kim S, Yegya-Raman N, Malhotra J, Groisberg R, Crayton SH, Silk AW, Nosher JL, Gentile MA, Mehnert JM, Jabbour SK. Wang SJ, et al. J Immunother Cancer. 2020 Oct;8(2):e000889. doi: 10.1136/jitc-2020-000889. J Immunother Cancer. 2020. PMID: 33020239 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

68 results

Results by year